Roche’s Mircera BLA Set Back Three Months For FDA Review Of New Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Delay could affect Amgen’s timeline for a potential filing of a preliminary injunction in its case against Roche, slated for trial in September.